SANOFI-AVENTIS Form 6-K August 08, 2005

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2005

Commission File Number: 001-31368

SANOFI-AVENTIS

(Translation of registrant s name into English)

174, avenue de France, 75013 Paris, FRANCE (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F x o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No x

If [Yes] marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-____

On August 5 and 8, 2005, sanofi-aventis issued the press releases attached hereto as Exhibits 99.1 and 99.2, which are incorporated herein by reference.

Exhibit List

<u>Exhibit No.</u>

Description

Exhibit 99.1 Press Release dated August 5, 2005, concerning the resolution of the Plavix[®] litigation in the United Kingdom
Exhibit 99.2 Press Release dated August 8, 2005, concerning the sale of sanofi-aventis' interests in Wacker-Chemie GmbH

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: August 8, 2005

SANOFI-AVENTIS

By: /s/ Jean-Pierre Kerjouan

Name: Jean-Pierre Kerjouan Title: Senior Vice President Advisor to the President

3

Exhibit Index

4

Exhibit No.

Description

Exhibit 99.1 Press Release dated August 5, 2005, concerning the resolution of the Plavix[®] litigation in the United Kingdom
Exhibit 99.2 Press Release dated August 8, 2005, concerning the sale of sanofi-aventis' interests in Wacker-Chemie GmbH

14,105.9936 D Common Stock

4,374.97 (2) (3) (4) I By Wife

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exercisable and	7. Title and	8. Price of	9. Nu
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transaction	onNumber	Expiration Date	Amount of	Derivative	Deriv
Security	or Exercise		any	Code	of	(Month/Day/Year)	Underlying	Security	Secu
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8) Derivative		ve	Securities	(Instr. 5)	Bene
	Derivative				Securities		(Instr. 3 and 4)		Owne

Edgar Filing: SANOFI-AVENTIS - Form 6-K

Security

Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) Code V (A) (D) Date Expiration Title Amount Exercisable Date or Number of Shares

Reporting Owners

Reporting Owner Name / Address						
	Director	10% Owner	Officer	Other		
HARRINGTON JOHN P C/O ENTERPRISE BANCORP 222 MERRIMACK STREET LOWELL, MA 01852	Х					
Signatures						
/s/ John P. Clancy, Jr. as attorney-in-fact for John P. Harrington						

**Signature of Reporting Person

2012

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Issued in lieu of cash for director compensation.
- (2) Includes 23.6705 shares acquired from the Issuer's dividend reinvestment plan on June 1, 2011.
- (3) Includes 34.0535 shares acquired from the Issuer's dividend reinvestment plan on September 1, 2011.
- (4) Includes 33.9896 shares acquired from the Issuer's dividend reinvestment plan on December 1, 2011.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.